KCRC Kidney Cancer RESEARCH CONSORTIUM

# A Phase 1b Study of HC-7366, an Agonist of ISR with immunotherapy in Kidney Cancer (SHARK)

ENROLLMENT:
**30 patients**

*at*

**Initiating Site:**

- UT Southwestern, Dr. Hans Hammers

Summary: The goal of this clinical research study is to find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The safety and effectiveness of these combinations will also be studied.

HC-7366 is not FDA approved or commercially available. At this time, it is being used in research only. Nivolumab and ipilimumab are both FDA approved and commercially available to treat multiple types of RCC, but their use in combination with HC-7366 is considered investigational. The study team can explain how these drugs are designed to work.

## Trial Schema

30 eligible patients

| Doublet Cohort (post-IO) | Triplet Cohort (front-line) |
|---|---|
| DOSE LEVEL ONE: 20 mg HC-7366 + nivolumab 480 mg IV Q4W | DOSE LEVEL ONE: 20mg HC-7366 + nivolumab 3mg/kg IV Q3W x4 + ipilimumab 1mg/kg IV Q3W x4 then 20mg HC-7366 + nivolumab 480mg IV Q4W |
| DOSE LEVEL TWO: 40 mg HC-7366 + nivolumab 480 mg IV Q4W | DOSE LEVEL TWO: 40mg HC-7366 + nivolumab 3mg/kg IV Q3W x4 + ipilimumab 1mg/kg IV Q3W x4 then 40mg HC-7366 + nivolumab 480mg IV Q4W |

Treat until PD or discontinuation

2-yr OS monitoring following discontinuation

## Key Criteria

- Clear Cell Renal Cell Carcinoma
- Metastatic Stage IV Disease
- ECOG 0, 1
- Adequate Organ Function
- Triplet Arm (IO/IO): No prior systemic therapy for advanced RCC or prior adjuvant therapy allowed.
- Doublet Arm: Patient must have progressed on at least one PD1 based doublet regimen (IO/IO or IO/TKI). Prior adjuvant therapy is allowed and does count as one line of systemic therapy.

*WOCBP: Women Of Child-Bearing Potential must not be pregnant and must utilize two forms of contraception while on treatment and for 23 weeks after treatment.*

*Men who are sexually active with WOCBP must agree to utilize acceptable contraception while on treatment and for 31 weeks after.*

**Drug Frequency:** You will take either Belzutifan daily for 12 weeks, Pembrolizumab every three weeks for 12 weeks (4 doses total), or you will take both Belzutifan daily *and* Pembrolizumab every three weeks for 12 weeks.

**Costs:** Belzutifan and/or pembrolizumab (whichever you are assigned to receive) will be provided at no cost to you during this study.

**Clinic Visit Frequency:** Patients visit the clinic every 3 weeks until surgery (12 weeks total), and then 30 days after surgery.